Ai-Media Technologies Ltd
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 610
- Market Cap
- $20.9M
- Introduction
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
- Conditions
- Long COVIDPost COVID-19 Condition
- Interventions
- Other: Placebo / Normal Saline
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- AIM ImmunoTech Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05592418
- Locations
- 🇺🇸
Hope Clinical Research, Canoga Park, California, United States
🇺🇸310 Clinical Research, Inglewood, California, United States
🇺🇸Acclaim Clinical Research, San Diego, California, United States
A Phase 2 Study to Evaluate the Efficacy and Safety of Ampligen® Compared to Control Group / No Treatment Following FOLFIRINOX in Subjects with Locally Advanced Pancreatic Adenocarcinoma
- Conditions
- locally advanced pancreatic cancer
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Aim Immunotech Inc.
- Target Recruit Count
- 30
- Registration Number
- 2024-518627-29-00
- Locations
- 🇳🇱
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam, Netherlands
Safety Study of FluMist With and Without Ampligen
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- AIM ImmunoTech Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT01591473
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
- Conditions
- HIV Infections
- Interventions
- Drug: Alferon LDO
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- AIM ImmunoTech Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT00215852
- Locations
- 🇺🇸
Drexel University School of Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Philadelphia FIGHTS, Philadelphia, Pennsylvania, United States
Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers
- Conditions
- Severe Acute Respiratory Syndrome
- Interventions
- Drug: Alferon LDO
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- AIM ImmunoTech Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00215826
- Locations
- 🇭🇰
Princess Margaret Hospital, Lai Chi Kok, Kowloon, Hong Kong
- Prev
- 1
- 2
- Next
News
AIM ImmunoTech Reports Promising Mid-Year Results from Phase 2 Pancreatic Cancer Combination Therapy Study
AIM ImmunoTech's Phase 2 DURIPANC study evaluating Ampligen combined with AstraZeneca's Imfinzi shows encouraging safety and efficacy signals in metastatic pancreatic cancer patients post-FOLFIRINOX treatment.
AIM ImmunoTech Secures Manufacturing Patent for Ampligen Through 2041
AIM ImmunoTech received U.S. patent No. 12312376 covering manufacturing methods for therapeutic double-stranded RNA products including Ampligen, extending protection until January 25, 2041.
AIM ImmunoTech Advances Ampligen Study as Potential Avian Flu Vaccine Booster with Promising Cross-Protection
AIM ImmunoTech initiates development of Ampligen as a vaccine adjuvant for avian influenza, partnering with Amarex Clinical Research for IND application management.
AIM ImmunoTech Advances to Phase 2 Trial of Ampligen-Imfinzi Combination for Late-Stage Pancreatic Cancer
Safety Committee grants approval for Phase 2 portion of AIM ImmunoTech's Phase 1b/2 trial evaluating Ampligen in combination with AstraZeneca's Imfinzi for late-stage pancreatic cancer treatment.
Ampligen Shows Potential in Treating Fatigue in Post-COVID Conditions, AIM ImmunoTech Announces
AIM ImmunoTech's AMP-518 study results support Ampligen as a potential therapeutic for moderate-to-severe Post-COVID fatigue.
AIM ImmunoTech Announces Clinical Milestones and Upcoming Studies for Ampligen
AIM ImmunoTech highlights the continued development of Ampligen (rintatolimod) across multiple clinical programs targeting pancreatic cancer and Long-COVID.
Novel Immunotherapy Approach Shows Promise in Triple-Negative Breast Cancer
A phase 1 clinical trial at Roswell Park Comprehensive Cancer Center reveals a promising new treatment for triple-negative breast cancer (TNBC).
NIH's RECOVER Initiative Shifts Focus to Clinical Trials for Long COVID Treatments
The NIH's RECOVER initiative is transitioning to RECOVER-TLC, prioritizing clinical trials for long COVID treatments, addressing the lack of approved therapies.
Rintatolimod and Durvalumab Combination Shows Promise in Late-Stage Pancreatic Cancer
Preliminary data from the DURIPANC trial indicates that rintatolimod plus durvalumab demonstrates early disease control in late-stage pancreatic cancer.